Drug Profile
XL 999
Alternative Names: EXEL-0999; XL-999Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Exelixis
- Developer Exelixis; Symphony Capital Partners
- Class Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor beta receptor antagonists; Type 1 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
- Discontinued Acute myeloid leukaemia; Colorectal cancer; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer in USA (IV, Infusion)
- 11 Jun 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the adverse events and Cancer therapeutic trials sections
- 07 Nov 2006 Clinical data from a media release have been added to the adverse events section